<DOC>
	<DOCNO>NCT02853162</DOCNO>
	<brief_summary>Phase II study ( n=30 ) evaluate safety feasibility stereotactic body radiation therapy ( SBRT ) fiducial marker inoperable patient renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>Ablative tReatment Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy ( ARREST-study )</brief_title>
	<detailed_description>Rationale : The standard treatment RCC ( partial- ) nephrectomy . Alternatives treatment le invasive technique like radio frequency ablation ( RFA ) cryoablation ( CA ) . Stereotactic body radiation therapy ( SBRT ) alternative curative treatment modality , show promising result several North-American phase I-II study last year . In study , aim evaluate safety feasibility SBRT patient inoperable RCC conventional cone beam compute tomography ( CBCT ) linear accelerator . Objective : To evaluate safety feasibility stereotactic body radiation therapy ( SBRT ) fiducial marker inoperable patient renal cell carcinoma ( RCC ) . Study design : Single arm prospective study . Study population : Inoperable patient ≥ 18 year , pathology proven RCC fulfil inclusion criterion . Intervention : Prior treatment , patient undergo fiducial marker placement ( combination biopsy , RCC pathology proven ) , follow contrast enhance planning compute tomography ( CT ) -scan contrast enhance MRI-scan . Fiducial marker use increase visibility tumor therefore accuracy radiotherapy , particularly irradiate healthy kidney tissue diminish use approach . Baseline toxicity quality life assess . SBRT use VMAT technique deliver five fraction 7 Gy every day . The target volume treatment define 4D planningCT MRI tumor treat midposition breathe cycle . After treatment , follow-up 1 , 3 , 6 12 month Radiotherapy department , follow standard follow-up urologist . An additional contrast enhance MRI scan perform 2nd treatment fraction , 6 12 month assess treatment response prepare future MR-guided ( MR-linac ) radiotherapy . Toxicity quality life assess follow-up . Main study parameters/endpoints : Newly develop acute toxicity grade 3 accord Common Terminology Criteria Adverse Events ( CTC-AE ) version 4.0 . The treatment consider successful 5 treatment complete total &lt; 15 % patient ( =5 patient ) report toxicity ≤ grade 3 . Secondary endpoint treatment response , ( late ) toxicity assessment , local control rate quality life assessment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inoperability , patient refuse surgery ( i.e . eligible ( partial ) nephrectomy RFA ) ; Kidney function allow intervention , evaluate treat urologist ( take account eGFR renogram ) ; Age ≥ 18 year ; Written inform consent ; Diagnosis RCC confirm pathology ( case determine informed consent , patient eligible anymore ( RCC ) exclude ) . Evidence metastatic disease ; Exclusion criterion contrast enhance MRI scan , accord protocol department Radiology , UMC Utrecht ; Patients one functioning kidney ; Prior renal surgery ( partial nephrectomy ) ; Prior radiotherapy upper abdomen ; Unsafe fiducial marker implantation : i.e . anticoagulant agent use acetylsalicyl acid , safely stopped/bridged implantation : WHO ≥ 3 . Chemotherapy &lt; 3 week treatment ; Targeted therapy ( sunitinib , etc . ) ≤ 7 day treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stereotactic body radiotherapy</keyword>
	<keyword>MRI</keyword>
	<keyword>Renal cell carcinoma</keyword>
</DOC>